Payment overview · 2025
General Payments
$104.21
5 reported records · 4 companies
Healthcare provider profile · identity verified
Vicky St John, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · JASPER, TX · NPI 1033580394
Verified facts
What the public records show
CMS Open Payments records show Vicky St John, APRN received $104.21 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Rybelsus.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.69 | 35.2% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $35.39 | 34.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.28 | 17.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.85 | 13.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $104.21 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $35.39 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $35.39 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 358 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 352 | 65 |
| Eliquis | Apixaban | 308 | 32 |
| Buspirone Hcl | Buspirone Hcl | 269 | 41 |
| Potassium Chloride | Potassium Chloride | 257 | 55 |
| Gabapentin | Gabapentin | 245 | 54 |
| Furosemide | Furosemide | 244 | 51 |
| Trazodone Hcl | Trazodone Hcl | 224 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 214 | 49 |
| Divalproex Sodium | Divalproex Sodium | 201 | 30 |
| Donepezil Hcl | Donepezil Hcl | 201 | 31 |
| Metformin Hcl | Metformin Hcl | 187 | 43 |
| Lisinopril | Lisinopril | 178 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 30 |
| Sertraline Hcl | Sertraline Hcl | 161 | 24 |
| Memantine Hcl | Memantine Hcl | 157 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 33 |
| Januvia | Sitagliptin Phosphate | 139 | 17 |
| Losartan Potassium | Losartan Potassium | 137 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 26 |
| Mirtazapine | Mirtazapine | 132 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 17 |
| Farxiga | Dapagliflozin Propanediol | 113 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 27 |
| Xarelto | Rivaroxaban | 98 | suppressed |
| Famotidine | Famotidine | 95 | 25 |
| Omeprazole | Omeprazole | 92 | 25 |
| Montelukast Sodium | Montelukast Sodium | 79 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 14 |
| Spironolactone | Spironolactone | 77 | 13 |
| Carvedilol | Carvedilol | 75 | 22 |
| Tramadol Hcl | Tramadol Hcl | 75 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 15 |
| Jardiance | Empagliflozin | 69 | 11 |
| Torsemide | Torsemide | 66 | 11 |
| Simvastatin | Simvastatin | 59 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 12 |
| Alendronate Sodium | Alendronate Sodium | 56 | 12 |
| Levetiracetam | Levetiracetam | 54 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 53 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | suppressed |
| Glipizide | Glipizide | 47 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Alprazolam | Alprazolam | 45 | 19 |
| Finasteride | Finasteride | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 16 |
| Allopurinol | Allopurinol | 42 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 41 | suppressed |
| Prednisone | Prednisone | 41 | 27 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 12 |
| Meloxicam | Meloxicam | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 25 |
| Digoxin | Digoxin | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 13 |
| Phenytek | Phenytoin Sodium Extended | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Nyamyc | Nystatin | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Cephalexin | Cephalexin | 16 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Pulmicort Flexhaler | Budesonide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | 12 |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Risperidone Er | Risperidone Microspheres | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $104.21 · 5 records | Novo Nordisk Inc | Flexitouch Plus, Nimbl, Ozempic, REXULTI, Rybelsus, The Cologuard Plus Collection Kit | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lundbeck LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error